Lobe Sciences Ltd News

Lobe Sciences Strengthens Board With Appointment of Biopharma Veteran | CSE:LOBE, OTCQB:LOBEF

Proactive InvestorsMay 31 05:28 ET

Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors

Physician, Fund Manager, Investor, InventorFormer Vice Chancellor at Vanderbilt University Medical CenterFormer Board Director For Renal Care Group and Kinetic ConceptsVANCOUVER, British Columbia--(BU

BusinesswireMay 30 07:30 ET

Lobe Sciences Appoints Dr Harry Jacobson to Its Board | CSE:LOBE, OTCQB:LOBEF

Proactive InvestorsMay 30 04:44 ET

Lobe Sciences Ltd. and Clearway Global Announce Change of Control and Focus on Creating Value for Shareholders

Lobe Sciences Ltd. ("Lobe" or the "Company") (OTCQB: LOBEF) (CSE: LOBE), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases and Clearway Global, LLC ("Clearway"), a wholly owned subsidiary of Sancilio & Company ("Sancilio"), a pharmaceutical services company focused on value creation strategies, are pleased to announce a change in control of the Company and several enhancements to its ongoing growth strategy.

BusinesswireMay 21 09:54 ET

Lobe Sciences Announces Change of Control | CSE:LOBE, OTCQB:LOBEF

Proactive InvestorsMay 21 06:32 ET

Lobe Sciences Provides Company Review of 2023

Stockhouse Jan 8 08:15 ET

Lobe Sciences Provides Update on L-130 Clinical Program

Stockhouse Dec 7, 2023 07:00 ET

Lobe Sciences Provides Update on L-130 Oral Psilocin Compound

Biopharmaceutical company Lobe Sciences Ltd. (LOBE.CSE), on Tuesday announced its lead clinical asset, L-130, a proprietary stabilized psilocin conjugate drug candidate, recently surpassed the 12-mon

MT NewswiresDec 5, 2023 08:37 ET

Lobe Sciences Appoints CFO

Lobe Sciences Ltd. (LOBE.CSE) said Monday that it has named Mathew Lee chief financial officer of the company. Lee currently serves as president of Manning Lee Management Ltd., a management consulting

MT NewswiresSep 18, 2023 13:46 ET

Lobe Sciences Amends Terms of Altemia Share Purchase Agreement

Lobe Sciences Ltd. (LOBE.CSE), a North American biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases, overnight Thursday said that i

MT NewswiresSep 15, 2023 06:50 ET

Lobe Sciences, Ltd. Provides Update on Vitamind

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discov

newsfileApr 21, 2023 17:06 ET

The Power Play by The Market Herald Releases New Interviews With ARway, Silver Bullet Mines, Galantas Gold, Lobe Sciences, Northstar Gold and Rover Metals Discussing Their Latest News

VANCOUVER, BC / ACCESSWIRE / April 19, 2023 / The Power Play by The Market Herald has announced the release of new interviews with ARway, Silver Bullet Mines, Galantas Gold, Lobe Sciences, Northstar G

AccesswireApr 19, 2023 14:40 ET

Lobe Sciences to Present at Sequire Cannabis & Psychedelics Conference April 5, 2023

Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") a North American Biopharmaceutical company committed to discove

newsfileApr 4, 2023 08:01 ET

Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130

Yahoo FinanceMar 22, 2023 09:08 ET

Lobe Sciences Ltd. Announces Exclusive Collaboration With Quality Chemical Laboratories LLC

Quality Chemical Laboratories LLC ("QCL") has developed a synthetic pathway for psilocybin, psilocin and psilocin analogues exclusively for Lobe SciencesQCL agrees to supply Lobe Sciences research and

newsfileFeb 21, 2023 08:31 ET

Lobe Sciences Ltd (LOBEF) Increases Its Portfolio With Several New Chemical Entities (NCEs)

AB Digital, Inc.Jan 19, 2023 06:10 ET

Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130

Vancouver, British Columbia--(Newsfile Corp. - November 30, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to dis

newsfileNov 30, 2022 09:15 ET

Lobe Sciences to Present at MONEYSHOW VIRTUAL EXPO November 10, 2022

Vancouver, British Columbia--(Newsfile Corp. - November 8, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") today announced that Philip Young, CEO and Executive Director

newsfileNov 8, 2022 09:20 ET

Lobe Sciences Announces the Completion of CGMP Production of Clinical Supplies For Upcoming Clinical Trials

Appointment of Philip J. Young, CEO, as Board ChairmanVancouver, British Columbia--(Newsfile Corp. - October 13, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Cana

newsfileOct 13, 2022 08:00 ET

Lobe Sciences Announces the Appointment of Baxter F. Phillips III to Its Board of Directors

Vancouver, British Columbia--(Newsfile Corp. - October 5, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering

newsfileOct 5, 2022 09:15 ET